Flowers Foods vs Danone SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Flowers Foods Inc (FLO)

Q3 202611 Aug – 5 Oct 2026

▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.
This is the core negative event that directly caused the stock to drop and reset expectations.
Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.
It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.
Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.
It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

September 202611 Aug – 5 Oct 2026

▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.
This is the core negative event that directly caused the stock to drop and reset expectations.
Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.
It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.
Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.
It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

Latest11 Aug – 5 Oct 2026

▼2

Flowers Foods hit by weak demand, guidance cut, and Tastykake sale plan

Q2 miss and 2026 guidance cut Flowers Foods reported Q2 sales down 4% to $1.19B, missing estimates, and cut full-year 2026 sales and EPS guidance below consensus. Management blamed pressured household budgets, shifting buying habits, and tough competition in fresh bread. The stock fell sharply as investors lowered expectations for future profits.
This is the core negative event that directly caused the stock to drop and reset expectations.
Weak demand from value-conscious consumers and GLP-1 drugs Palm Valley Capital noted that demand for Flowers' bread and bakery products is being hurt by cost-conscious shoppers and the growing use of GLP-1 weight-loss medications. These trends reduce how much bread people buy, pressuring sales and profits. The fund expects near-term conditions to stay challenging.
It explains a deeper, ongoing demand problem that affects future revenue, not just one quarter.
Exploring sale of Tastykake unit for about $350 million Flowers Foods is exploring a sale of its Tastykake division, which could bring in around $350 million. The move fits its plan to shed non-core brands and focus on higher-growth snack brands like Simple Mills. A sale could raise cash and simplify the business, but it also removes a $400 million revenue stream, so the market impact is uncertain.
It is a major strategic action that could reshape the company and affect its value, though the outcome is not yet clear.

Danone SA (BN.PA)

Q3 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

July 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

Latest22 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.